Revenue

A fintech firm's new hire seems distant, but it signals a crucial shift in how capital flows into life-saving research and healthcare innovation.

As Natuzzi prepares its Q3 results, the luxury furniture maker's costly bet on Italian craftsmanship faces a critical test amid a tough economy.

Quince Therapeutics' Phase 3 trial completion for Ataxia-Telangiectasia offers hope, but the real story is its innovative red blood cell drug delivery platform.

A decade after his passing, a hyper-exclusive David Bowie tribute redefines luxury, blending musical authenticity with bespoke hospitality for a new class of investor.

MCF Advisors' acquisition of AWM, its first since a major PE investment, pushes its AUM to $3.9B and showcases the playbook reshaping regional wealth.

The SKIPPY and Milk Bar partnership reveals more than a secret recipe; it’s a masterclass in turning supply chain logistics into brand equity.

Quipt Home Medical's acquisition by private equity offers a massive premium to shareholders and sets the stage for aggressive M&A in the home respiratory care market.

A new drug for a leading cause of blindness missed its primary goal, yet its unique ability to improve vision offers new hope for millions of patients.

Natera's legal retreat solidifies a major victory for NeoGenomics, clearing the runway for its RaDaR ST launch and shaking the diagnostic patent landscape.

A junior miner begins a high-stakes drill program in Arizona, betting on advanced geology to find the copper essential for the world's energy transition.

Talen Energy unveils a major executive overhaul and a novel compensation plan, signaling a strategic pivot to dominate the energy-hungry AI data center market.

A public fund's major investment in Consensys, the firm behind MetaMask, signals growing institutional confidence in Web3's foundational infrastructure.

A pivotal trial success in lupus for BTK inhibitor orelabrutinib not only offers new hope for patients but also validates Zenas BioPharma's strategy.

Vanda Pharmaceuticals submits its novel GPP therapy, imsidolimab, for FDA review, offering new hope for patients and bolstering its rare disease portfolio.

The crypto giant reports massive growth, but a pivot to AI, operational fires, and rising debt reveal a risky strategy to reshape global computing power.

As New Jersey's cannabis market booms, Grown Rogue's one-year success reveals a potent strategy for blending craft quality with low-cost execution.

JCDecaux's new AI measures MTR audiences with precision, but can it win public trust by balancing data insights with total anonymity?

A complex share buyback and reverse stock split reveal Havas's deeper strategy: shoring up its finances to invest in a new era of health communication.

Radisson Hotel Group and SMHCC ink a deal for three new hotels, a strategic move to dominate the MICE market and capitalize on the Philippines' resurgence.

A moving company hosts a governor, revealing the complex logistics and infrastructure network profiting from America's massive wealth redistribution.